Regeneron Promotes Yancopoulos to Chief Scientific Officer; Also Names Valenzuela Vice President.

TARRYTOWN, N.Y.--(BW HealthWire)--Jan. 14, 1998--Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) announced that George D. Yancopoulos, M.D., Ph.D., Senior Vice President of Research, has also been named Chief Scientific Officer of the Company. Dr. Yancopoulos joined Regeneron as a founding scientist in 1989 and served as Vice President, Discovery, from January 1992 until June 1997, when he was named Senior Vice President of Research.

Under Dr. Yancopoulos's direction, Regeneron's molecular and cell biology scientists have made a number of landmark discoveries and breakthroughs, many of which are the subject of active research and development programs with potential clinical applications ranging from neurodegenerative diseases to cancer and revascularization of ischemic tissue. Much of this work formed the basis of the Company's broad, long-term collaboration with The Procter & Gamble Company.

"Regeneron's discovery organization has demonstrated remarkable creativity, drive, and productivity, providing key scientific insights that have been published in many of the world's most respected scientific journals. According to citation rankings compiled by the Institute for Scientific Information, Dr. Yancopoulos is the only industry scientist among the ten most highly cited researchers in biomedicine during the 1990s," said Leonard S. Schleifer, M.D., Ph.D., President and Chief Executive Officer.

Dr. Yancopoulos received his M.D. and his Ph.D. in Biochemistry and Molecular Biophysics from Columbia University. From 1988 to 1989, Dr. Yancopoulos was a Lucille P. Markey Scholar at Columbia University.

Regeneron also announced that David M. Valenzuela, Ph.D., was named Vice President, Genomics and Bioinformatics. He joined the Company in 1990 and most recently was Senior Director, Genomics and Bioinformatics. Dr. Valenzuela obtained his Ph.D. in molecular biology from the Albert Einstein College of Medicine, Yeshiva University. "David is responsible for the identification and cloning of novel genes that serve as targets for drug screens. This effort builds on Regeneron's internal discovery efforts, as well as the human genome initiative. David has made many key discoveries for Regeneron in the last four years, and we believe that in his new position David will continue to make important contributions to the Company's drug discovery programs," said Dr. Yancopoulos.

Regeneron is a leader in the application of molecular and cell biology to the search for novel human therapeutics. Regeneron uses its expertise in growth factors and their mechanisms of action to discover and develop protein-based and small molecule drugs for the treatment of neurological, inflammatory, and muscle diseases, as well as abnormal bone growth, obesity, cancer, and angiogenesis. Amgen-Regeneron Partners is conducting human clinical studies of Regeneron's brain-derived neurotrophic factor (BDNF) and neurotrophin-3 (NT-3). The Company has a number of research collaborations, including a broad-based, long-term agreement with The Procter & Gamble Company.

This news release discusses historical information and includes forward looking statements about Regeneron's products, programs, finances, and business, all of which involve a number of risks and uncertainties, such as risks associated with preclinical and clinical development of drugs and biologics, determinations by regulatory and administrative governmental authorities, competitive factors, technological developments, the availability and cost of capital, the costs of developing, producing, and selling products, the potential for any collaboration agreement to be canceled or to terminate without any product success, and other material risks. A more complete description of these risks can be found in Regeneron's Form 10-K for the year ended December 31, 1996 and current Form 10-Q, copies of which should be read before making any investment decision regarding Regeneron common stock. -0- Regeneron's recent news releases can be obtained by dialing [phone] for fax copies or by accessing the Internet at www.businesswire.com

CONTACT: Murray A. Goldberg,

Vice President Finance and Administration and CFO 

Regeneron Pharmaceuticals, Inc.

[phone]

or

Michael Gross, Partner

Robinson Lerer & Montgomery

[phone]